1
|
Ellis ML, Terreaux A, Alwis I, Smythe R, Perdomo J, Eckly A, Cranmer SL, Passam FH, Maclean J, Schoenwaelder SM, Ruggeri ZM, Lanza F, Taoudi S, Yuan Y, Jackson SP. GPIbα-filamin A interaction regulates megakaryocyte localization and budding during platelet biogenesis. Blood 2024; 143:342-356. [PMID: 37922495 DOI: 10.1182/blood.2023021292] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/27/2023] [Accepted: 10/24/2023] [Indexed: 11/05/2023] Open
Abstract
ABSTRACT Glycoprotein Ibα (GPIbα) is expressed on the surface of platelets and megakaryocytes (MKs) and anchored to the membrane skeleton by filamin A (flnA). Although GPIb and flnA have fundamental roles in platelet biogenesis, the nature of this interaction in megakaryocyte biology remains ill-defined. We generated a mouse model expressing either human wild-type (WT) GPIbα (hGPIbαWT) or a flnA-binding mutant (hGPIbαFW) and lacking endogenous mouse GPIbα. Mice expressing the mutant GPIbα transgene exhibited macrothrombocytopenia with preserved GPIb surface expression. Platelet clearance was normal and differentiation of MKs to proplatelets was unimpaired in hGPIbαFW mice. The most striking abnormalities in hGPIbαFW MKs were the defective formation of the demarcation membrane system (DMS) and the redistribution of flnA from the cytoplasm to the peripheral margin of MKs. These abnormalities led to disorganized internal MK membranes and the generation of enlarged megakaryocyte membrane buds. The defective flnA-GPIbα interaction also resulted in misdirected release of buds away from the vasculature into bone marrow interstitium. Restoring the linkage between flnA and GPIbα corrected the flnA redistribution within MKs and DMS ultrastructural defects as well as restored normal bud size and release into sinusoids. These studies define a new mechanism of macrothrombocytopenia resulting from dysregulated MK budding. The link between flnA and GPIbα is not essential for the MK budding process, however, it plays a major role in regulating the structure of the DMS, bud morphogenesis, and the localized release of buds into the circulation.
Collapse
Affiliation(s)
- Marc L Ellis
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
| | - Antoine Terreaux
- Blood Cell Formation Lab, Walter and Eliza Hall Institute, Parkville, VIC, Australia
| | - Imala Alwis
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
| | - Rhyll Smythe
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
| | - Jose Perdomo
- Haematology Research Unit, St George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Anita Eckly
- Université de Strasbourg, INSERM, French Blood Establishment (EFS) Grand Est, BPPS UMR-S 1255, FMTS, Strasbourg, France
| | - Susan L Cranmer
- Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia
| | - Freda H Passam
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
| | - Jessica Maclean
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
| | - Simone M Schoenwaelder
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
- School of Medical Sciences, University of Sydney, Camperdown, NSW, Australia
| | - Zaverio M Ruggeri
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA
| | - Francois Lanza
- Université de Strasbourg, INSERM, French Blood Establishment (EFS) Grand Est, BPPS UMR-S 1255, FMTS, Strasbourg, France
| | - Samir Taoudi
- Blood Cell Formation Lab, Walter and Eliza Hall Institute, Parkville, VIC, Australia
- The University of Melbourne, Parkville, VIC, Australia
| | - Yuping Yuan
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
| | - Shaun P Jackson
- Thrombosis Research Group, The Heart Institute, Newtown, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA
| |
Collapse
|
2
|
Beck S, Öftering P, Li R, Hemmen K, Nagy M, Wang Y, Zarpellon A, Schuhmann MK, Stoll G, Ruggeri ZM, Heinze KG, Heemskerk JW, Ruf W, Stegner D, Nieswandt B. Platelet glycoprotein V spatio-temporally controls fibrin formation. Nat Cardiovasc Res 2023; 2:368-382. [PMID: 37206993 PMCID: PMC10195106 DOI: 10.1038/s44161-023-00254-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 02/15/2023] [Indexed: 05/21/2023]
Abstract
The activation of platelets and coagulation at vascular injury sites is crucial for haemostasis but can promote thrombosis and inflammation in vascular pathologies. Here, we delineate an unexpected spatio-temporal control mechanism of thrombin activity that is platelet orchestrated and locally limits excessive fibrin formation after initial haemostatic platelet deposition. During platelet activation, the abundant platelet glycoprotein (GP) V is cleaved by thrombin. We demonstrate with genetic and pharmacological approaches that thrombin-mediated shedding of GPV does not primarily regulate platelet activation in thrombus formation, but rather has a distinct function after platelet deposition and specifically limits thrombin-dependent generation of fibrin, a crucial mediator of vascular thrombo-inflammation. Genetic or pharmacologic defects in haemostatic platelet function are unexpectedly attenuated by specific blockade of GPV shedding, indicating that the spatio-temporal control of thrombin-dependent fibrin generation also represents a potential therapeutic target to improve haemostasis.
Collapse
Affiliation(s)
- Sarah Beck
- Julius-Maximilians-Universität Würzburg, Rudolf Virchow Center for Integrative and Translational Bioimaging, Würzburg, Germany
- University Hospital Würzburg, Institute of Experimental Biomedicine, Würzburg, Germany
| | - Patricia Öftering
- Julius-Maximilians-Universität Würzburg, Rudolf Virchow Center for Integrative and Translational Bioimaging, Würzburg, Germany
- University Hospital Würzburg, Institute of Experimental Biomedicine, Würzburg, Germany
| | - Renhao Li
- Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine; Atlanta, USA
| | - Katherina Hemmen
- Julius-Maximilians-Universität Würzburg, Rudolf Virchow Center for Integrative and Translational Bioimaging, Würzburg, Germany
| | - Magdolna Nagy
- Department of Biochemistry, CARIM, Maastricht University; Maastricht, The Netherlands
| | - Yingchun Wang
- Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine; Atlanta, USA
| | | | | | - Guido Stoll
- University Hospital Würzburg, Department of Neurology, Würzburg, Germany
| | | | - Katrin G. Heinze
- Julius-Maximilians-Universität Würzburg, Rudolf Virchow Center for Integrative and Translational Bioimaging, Würzburg, Germany
| | - Johan W.M. Heemskerk
- Department of Biochemistry, CARIM, Maastricht University; Maastricht, The Netherlands
| | - Wolfram Ruf
- Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University Medical Center Mainz; Mainz, Germany
- Department of Immunology and Microbiology, Scripps Research; La Jolla, CA, USA
| | - David Stegner
- Julius-Maximilians-Universität Würzburg, Rudolf Virchow Center for Integrative and Translational Bioimaging, Würzburg, Germany
- University Hospital Würzburg, Institute of Experimental Biomedicine, Würzburg, Germany
- Correspondence and requests for materials should be addressed to: ,
| | - Bernhard Nieswandt
- Julius-Maximilians-Universität Würzburg, Rudolf Virchow Center for Integrative and Translational Bioimaging, Würzburg, Germany
- University Hospital Würzburg, Institute of Experimental Biomedicine, Würzburg, Germany
- Correspondence and requests for materials should be addressed to: ,
| |
Collapse
|
3
|
Morodomi Y, Kanaji S, Sullivan BM, Zarpellon A, Orje JN, Won E, Shapiro R, Yang XL, Ruf W, Schimmel P, Ruggeri ZM, Kanaji T. Inflammatory platelet production stimulated by tyrosyl-tRNA synthetase mimicking viral infection. Proc Natl Acad Sci U S A 2022; 119:e2212659119. [PMID: 36409883 PMCID: PMC9860251 DOI: 10.1073/pnas.2212659119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 10/20/2022] [Indexed: 11/22/2022] Open
Abstract
Platelets play a role not only in hemostasis and thrombosis, but also in inflammation and innate immunity. We previously reported that an activated form of tyrosyl-tRNA synthetase (YRSACT) has an extratranslational activity that enhances megakaryopoiesis and platelet production in mice. Here, we report that YRSACT mimics inflammatory stress inducing a unique megakaryocyte (MK) population with stem cell (Sca1) and myeloid (F4/80) markers through a mechanism dependent on Toll-like receptor (TLR) activation and type I interferon (IFN-I) signaling. This mimicry of inflammatory stress by YRSACT was studied in mice infected by lymphocytic choriomeningitis virus (LCMV). Using Sca1/EGFP transgenic mice, we demonstrated that IFN-I induced by YRSACT or LCMV infection suppressed normal hematopoiesis while activating an alternative pathway of thrombopoiesis. Platelets of inflammatory origin (Sca1/EGFP+) were a relevant proportion of those circulating during recovery from thrombocytopenia. Analysis of these "inflammatory" MKs and platelets suggested their origin in myeloid/MK-biased hematopoietic stem cells (HSCs) that bypassed the classical MK-erythroid progenitor (MEP) pathway to replenish platelets and promote recovery from thrombocytopenia. Notably, inflammatory platelets displayed enhanced agonist-induced activation and procoagulant activities. Moreover, myeloid/MK-biased progenitors and MKs were mobilized from the bone marrow, as evidenced by their presence in the lung microvasculature within fibrin-containing microthrombi. Our results define the function of YRSACT in platelet generation and contribute to elucidate platelet alterations in number and function during viral infection.
Collapse
Affiliation(s)
- Yosuke Morodomi
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA92037
- The Scripps Laboratories for tRNA Synthetase Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA92037
| | - Sachiko Kanaji
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA92037
- The Scripps Laboratories for tRNA Synthetase Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA92037
| | - Brian M. Sullivan
- Viral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA92037
| | | | - Jennifer N. Orje
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA92037
- MERU-VasImmune, Inc., San Diego, CA92121
| | - Eric Won
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA92037
- Department of Hematology and Oncology, University of California, San Diego, CA92093
- Rady Children’s Hospital, San Diego, CA92123
| | - Ryan Shapiro
- The Scripps Laboratories for tRNA Synthetase Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA92037
| | - Xiang-Lei Yang
- The Scripps Laboratories for tRNA Synthetase Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA92037
| | - Wolfram Ruf
- Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, 55128Germany
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA92037
| | - Paul Schimmel
- The Scripps Laboratories for tRNA Synthetase Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA92037
| | - Zaverio M. Ruggeri
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA92037
- MERU-VasImmune, Inc., San Diego, CA92121
| | - Taisuke Kanaji
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA92037
- The Scripps Laboratories for tRNA Synthetase Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA92037
| |
Collapse
|
4
|
Aiolfi R, Sitia G, Iannacone M, Brunetta I, Guidotti LG, Ruggeri ZM. Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets. Sci Signal 2022; 15:eabb0384. [PMID: 35192415 DOI: 10.1126/scisignal.abb0384] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Bleeding correlates with disease severity in viral hemorrhagic fevers. We found that the increase in type I interferon (IFN-I) in mice caused by infection with the Armstrong strain of lymphocytic choriomeningitis virus (LCMV; an arenavirus) reduced the megakaryocytic expression of genes encoding enzymes involved in lipid biosynthesis (cyclooxygenase 1 and thromboxane A synthase 1) and a thrombopoietic transcription factor (Nf-e2). The decreased expression of these genes was associated with reduced numbers of circulating platelets and defects in the arachidonic acid synthetic pathway, thereby suppressing serotonin release from δ-granules in platelets. Bleeding resulted when severe thrombocytopenia and altered platelet function reduced the amount of platelet-derived serotonin below a critical threshold. Bleeding was facilitated by the absence of the activity of the kinase Lyn or the administration of aspirin, an inhibitor of arachidonic acid synthesis. Mouse platelets were not directly affected by IFN-I because they lack the receptor for the cytokine (IFNAR1), suggesting that transfusion of normal platelets into LCMV-infected mice could increase the amount of platelet-released serotonin and help to control hemorrhage.
Collapse
Affiliation(s)
- Roberto Aiolfi
- Department of Molecular Medicine, MERU-Roon Research Center for Vascular Biology, Scripps Research, La Jolla, CA 92037, USA.,Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.,Vita-Salute San Raffaele University, Milan, Italy
| | - Giovanni Sitia
- Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Matteo Iannacone
- Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.,Vita-Salute San Raffaele University, Milan, Italy.,Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Ivan Brunetta
- Department of Molecular Medicine, MERU-Roon Research Center for Vascular Biology, Scripps Research, La Jolla, CA 92037, USA
| | - Luca G Guidotti
- Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.,Vita-Salute San Raffaele University, Milan, Italy
| | - Zaverio M Ruggeri
- Department of Molecular Medicine, MERU-Roon Research Center for Vascular Biology, Scripps Research, La Jolla, CA 92037, USA
| |
Collapse
|
5
|
Kanaji S, Morodomi Y, Weiler H, Zarpellon A, Montgomery RR, Ruggeri ZM, Kanaji T. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse. Haematologica 2022; 107:2133-2143. [PMID: 35142156 PMCID: PMC9425322 DOI: 10.3324/haematol.2021.280561] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Indexed: 11/24/2022] Open
Abstract
Type 2B von Willebrand disease (VWD) is caused by gain-of-function mutations in von Willebrand factor (VWF). Increased VWF affinity for GPIbα results in loss of high molecular weight multimers and enhanced platelet clearance, both contributing to the bleeding phenotype. Severity of the symptoms vary among type 2B VWD patients, with some developing thrombocytopenia only under stress conditions. Efforts have been made to study underlying pathophysiology for platelet abnormalities, but animal studies have been limited because of species specificity in the VWF-GPIbα interaction. Here, we generated a severe form of type 2B VWD (p.V1316M) knockin mice in the context of human VWF exon 28 (encoding A1 and A2 domains) and crossed them with human GPIbα transgenic strain. Heterozygous mutant mice recapitulated the phenotype of type 2B VWD in autosomal dominant manner and presented severe macrothrombocytopenia. Of note, platelets remaining in the circulation had extracytoplasmic GPIbα shed-off from the cell surface. Reciprocal bone marrow transplantation determined mutant VWF produced from endothelial cells as the major cause of the platelet phenotype in type 2B VWD mice. Moreover, altered megakaryocyte maturation in the bone marrow and enhanced extramedullary megakaryopoiesis in the spleen were observed. Interestingly, injection of anti-VWF A1 blocking antibody (NMC-4) not only ameliorated platelet count and GPIbα expression, but also reversed MK ploidy shift. In conclusion, we present a type 2B VWD mouse model with humanized VWF-GPIbα interaction which demonstrated direct influence of aberrant VWF-GPIbα binding on megakaryocytes.
Collapse
Affiliation(s)
- Sachiko Kanaji
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee.
| | - Yosuke Morodomi
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla
| | - Hartmut Weiler
- Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee
| | - Alessandro Zarpellon
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; MERU-VasImmune, Inc., San Diego
| | - Robert R Montgomery
- Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee, WI; Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226
| | - Zaverio M Ruggeri
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; MERU-VasImmune, Inc., San Diego
| | - Taisuke Kanaji
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee
| |
Collapse
|
6
|
Affiliation(s)
- Zaverio M Ruggeri
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA.
| | - Wolfram Ruf
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. .,Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany.
| |
Collapse
|
7
|
Won E, Morodomi Y, Kanaji S, Shapiro R, Vo M, Orje JN, Thornburg CD, Yang X, Ruggeri ZM, Schimmel P, Kanaji T. Extracellular tyrosyl-tRNA synthetase cleaved by plasma proteinases and stored in platelet α-granules: Potential role in monocyte activation. Res Pract Thromb Haemost 2020; 4:1167-1177. [PMID: 33134783 PMCID: PMC7590329 DOI: 10.1002/rth2.12429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 08/18/2020] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Tyrosyl-tRNA synthetase (YRS) belongs to the family of enzymes that catalyzes the tRNA aminoacylation reaction for protein synthesis, and it has been recently shown to exert noncanonical functions. Although database results indicate extremely low levels of YRS mRNA in platelets, YRS protein is abundantly present. The source of YRS in platelets, as well as the physiological role of platelet-stored YRS, remains largely unknown. OBJECTIVES To clarify how YRS accumulates in platelets and determine the potential role of platelet-stored YRS. METHODS Recombinant YRS proteins with epitope tags were prepared and tested in vitro for proteolytic cleavage in human plasma. Fluorescent-labeled YRS was examined for uptake by platelets, as demonstrated by western blotting and confocal microscopy analysis. Using RAW-Dual reporter cells, Toll-like receptor and type I interferon activation pathways were analyzed after treatment with YRS. RESULTS Full-length YRS was cleaved by both elastase and matrix metalloproteinases in the plasma. The cleaved, N-terminal YRS fragment corresponds to the endogenous YRS detected in platelet lysate by western blotting. Both full-length and cleaved forms of YRS were taken up by platelets in vitro and stored in the α-granules. The N-terminal YRS fragment generated by proteolytic cleavage had monocyte activation comparable to that of the constitutive-active mutant YRS (YRSY341A) previously reported. CONCLUSION Platelets take up both full-length YRS and the active form of cleaved YRS fragment from the plasma. The cleaved, N-terminal YRS fragment stored in α-granules may have potential to activate monocytes.
Collapse
Affiliation(s)
- Eric Won
- Department of Molecular MedicineMERU‐Roon Research Center on Vascular BiologyThe Scripps Research InstituteLa JollaCaliforniaUSA
- Division of Hematology/OncologyDepartment of PediatricsUC San Diego School of MedicineLa JollaCaliforniaUSA
- Hemophilia and Thrombosis Treatment CenterRady Children's HospitalSan DiegoCaliforniaUSA
| | - Yosuke Morodomi
- Department of Molecular MedicineMERU‐Roon Research Center on Vascular BiologyThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - Sachiko Kanaji
- Department of Molecular MedicineMERU‐Roon Research Center on Vascular BiologyThe Scripps Research InstituteLa JollaCaliforniaUSA
- Department of Molecular MedicineThe Scripps Laboratories for tRNA Synthetase ResearchThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - Ryan Shapiro
- Department of Molecular MedicineThe Scripps Laboratories for tRNA Synthetase ResearchThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - My‐Nuong Vo
- Department of Molecular MedicineThe Scripps Laboratories for tRNA Synthetase ResearchThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - Jennifer N. Orje
- Department of Molecular MedicineMERU‐Roon Research Center on Vascular BiologyThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - Courtney D. Thornburg
- Division of Hematology/OncologyDepartment of PediatricsUC San Diego School of MedicineLa JollaCaliforniaUSA
- Hemophilia and Thrombosis Treatment CenterRady Children's HospitalSan DiegoCaliforniaUSA
| | - Xiang‐Lei Yang
- Department of Molecular MedicineThe Scripps Laboratories for tRNA Synthetase ResearchThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - Zaverio M. Ruggeri
- Department of Molecular MedicineMERU‐Roon Research Center on Vascular BiologyThe Scripps Research InstituteLa JollaCaliforniaUSA
| | - Paul Schimmel
- Department of Molecular MedicineThe Scripps Laboratories for tRNA Synthetase ResearchThe Scripps Research InstituteLa JollaCaliforniaUSA
- Department of Molecular MedicineThe Scripps Research InstituteJupiterFloridaUSA
| | - Taisuke Kanaji
- Department of Molecular MedicineMERU‐Roon Research Center on Vascular BiologyThe Scripps Research InstituteLa JollaCaliforniaUSA
| |
Collapse
|
8
|
Zilberman-Rudenko J, Deguchi H, Shukla M, Oyama Y, Orje JN, Guo Z, Wyseure T, Mosnier LO, McCarty OJT, Ruggeri ZM, Eckle T, Griffin JH. Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. Arterioscler Thromb Vasc Biol 2020; 40:901-913. [PMID: 32102568 DOI: 10.1161/atvbaha.120.313990] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVE Cardiac myosin (CM) is structurally similar to skeletal muscle myosin, which has procoagulant activity. Here, we evaluated CM's ex vivo, in vivo, and in vitro activities related to hemostasis and thrombosis. Approach and Results: Perfusion of fresh human blood over CM-coated surfaces caused thrombus formation and fibrin deposition. Addition of CM to blood passing over collagen-coated surfaces enhanced fibrin formation. In a murine ischemia/reperfusion injury model, exogenous CM, when administered intravenously, augmented myocardial infarction and troponin I release. In hemophilia A mice, intravenously administered CM reduced tail-cut-initiated bleeding. These data provide proof of concept for CM's in vivo procoagulant properties. In vitro studies clarified some mechanisms for CM's procoagulant properties. Thrombin generation assays showed that CM, like skeletal muscle myosin, enhanced thrombin generation in human platelet-rich and platelet-poor plasmas and also in mixtures of purified factors Xa, Va, and prothrombin. Binding studies showed that CM, like skeletal muscle myosin, directly binds factor Xa, supporting the concept that the CM surface is a site for prothrombinase assembly. In tPA (tissue-type plasminogen activator)-induced plasma clot lysis assays, CM was antifibrinolytic due to robust CM-dependent thrombin generation that enhanced activation of TAFI (thrombin activatable fibrinolysis inhibitor). CONCLUSIONS CM in vitro is procoagulant and prothrombotic. CM in vivo can augment myocardial damage and can be prohemostatic in the presence of bleeding. CM's procoagulant and antifibrinolytic activities likely involve, at least in part, its ability to bind factor Xa and enhance thrombin generation. Future work is needed to clarify CM's pathophysiology and its mechanistic influences on hemostasis or thrombosis.
Collapse
Affiliation(s)
- Jevgenia Zilberman-Rudenko
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.).,Department of Biomedical Engineering (J.Z.-R., O.J.T.M.), School of Medicine, Oregon Health & Science University, Portland
| | - Hiroshi Deguchi
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Meenal Shukla
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Yoshimasa Oyama
- Department of Hematology-Oncology (O.J.T.M.), School of Medicine, Oregon Health & Science University, Portland
| | - Jennifer N Orje
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Zihan Guo
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Tine Wyseure
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Laurent O Mosnier
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Owen J T McCarty
- Department of Biomedical Engineering (J.Z.-R., O.J.T.M.), School of Medicine, Oregon Health & Science University, Portland
| | - Zaverio M Ruggeri
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.)
| | - Tobias Eckle
- Department of Hematology-Oncology (O.J.T.M.), School of Medicine, Oregon Health & Science University, Portland
| | - John H Griffin
- From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA (J.Z.-R., H.D., M.S., J.N.O., Z.G., T.W., L.O.M., Z.M.R., J.H.G.).,Department of Anesthesiology, University of Colorado School of Medicine, Aurora (Y.O., T.E.)
| |
Collapse
|
9
|
Abstract
von Willebrand factor (VWF) is a multimeric protein composed of monomeric subunits (∼280 kD) linked by disulfide bonds. During hemostasis and thrombosis, ultralarge (UL) VWF (ULVWF) multimers initiate platelet adhesion. In vitro, human C3 binds to ULVWF multimeric strings secreted by and anchored to human endothelial cell to promote the assembly and activation of C3 convertase (C3bBb) and C5 convertase (C3bBbC3b) of the alternative complement pathway (AP). The purified and soluble C3 avidly binds to recombinant human VWF A1A2A3, as well as the recombinant isolated human VWF A3 domain. Notably, the binding of soluble human ULVWF multimers to purified human C3 was blocked by addition of a monovalent Fab fragment antibody to the VWF A3 domain. We conclude that the A3 domain in VWF/ULVWF contains a docking site for C3. In contrast, purified human C4, an essential component of the classical and lectin complement pathways, binds to soluble, isolated A1, but not to ULVWF strings secreted by and anchored to endothelial cells. Our findings should facilitate the design of new therapeutic agents to suppress the initiation of the AP on ULVWF multimeric strings during thrombotic and inflammatory disorders.
Collapse
Affiliation(s)
- Jennifer G Nolasco
- Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States
| | - Leticia H Nolasco
- Department of Bioengineering, Rice University, Houston, Texas, United States
| | - Qi Da
- Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States.,Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, Texas, United States
| | - Sonya Cirlos
- Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States.,Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, Texas, United States
| | - Zaverio M Ruggeri
- Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, California, United States
| | - Joel L Moake
- Department of Bioengineering, Rice University, Houston, Texas, United States
| | - Miguel A Cruz
- Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States.,Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, Texas, United States
| |
Collapse
|
10
|
Xu XR, Wang Y, Adili R, Ju L, Spring CM, Jin JW, Yang H, Neves MAD, Chen P, Yang Y, Lei X, Chen Y, Gallant RC, Xu M, Zhang H, Song J, Ke P, Zhang D, Carrim N, Yu SY, Zhu G, She YM, Cyr T, Fu W, Liu G, Connelly PW, Rand ML, Adeli K, Freedman J, Lee JE, Tso P, Marchese P, Davidson WS, Jackson SP, Zhu C, Ruggeri ZM, Ni H. Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis. Nat Commun 2018; 9:3608. [PMID: 30190457 PMCID: PMC6127106 DOI: 10.1038/s41467-018-05806-0] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2017] [Accepted: 07/19/2018] [Indexed: 12/29/2022] Open
Abstract
Platelet αIIbβ3 integrin and its ligands are essential for thrombosis and hemostasis, and play key roles in myocardial infarction and stroke. Here we show that apolipoprotein A-IV (apoA-IV) can be isolated from human blood plasma using platelet β3 integrin-coated beads. Binding of apoA-IV to platelets requires activation of αIIbβ3 integrin, and the direct apoA-IV-αIIbβ3 interaction can be detected using a single-molecule Biomembrane Force Probe. We identify that aspartic acids 5 and 13 at the N-terminus of apoA-IV are required for binding to αIIbβ3 integrin, which is additionally modulated by apoA-IV C-terminus via intra-molecular interactions. ApoA-IV inhibits platelet aggregation and postprandial platelet hyperactivity. Human apoA-IV plasma levels show a circadian rhythm that negatively correlates with platelet aggregation and cardiovascular events. Thus, we identify apoA-IV as a novel ligand of αIIbβ3 integrin and an endogenous inhibitor of thrombosis, establishing a link between lipoprotein metabolism and cardiovascular diseases. Activation of integrin αIIbβ3 at the surface of platelets is required for their aggregation and for thrombus formation. Here Xu et al. identify apolipoprotein A-IV as a novel ligand for platelet αIIbβ3 integrin, and find it inhibits platelet aggregation and thrombosis.
Collapse
Affiliation(s)
- Xiaohong Ruby Xu
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510120.,Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510000
| | - Yiming Wang
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Reheman Adili
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Lining Ju
- Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA, 30332.,Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA, 30332.,Heart Research Institute, and Charles Perkins Centre, The University of Sydney, Camperdown, Australia, 2006
| | - Christopher M Spring
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Joseph Wuxun Jin
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Hong Yang
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Miguel A D Neves
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Pingguo Chen
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Yan Yang
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Xi Lei
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Yunfeng Chen
- Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA, 30332.,Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA, 30332
| | - Reid C Gallant
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Miao Xu
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Hailong Zhang
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Jina Song
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Peifeng Ke
- Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510000.,Department of Laboratory Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510120
| | - Dan Zhang
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510000
| | - Naadiya Carrim
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1
| | - Si-Yang Yu
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China, 410011
| | - Guangheng Zhu
- Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Yi-Min She
- Centre for Biologics Research, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON, Canada, K1A 0M2
| | - Terry Cyr
- Centre for Biologics Research, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON, Canada, K1A 0M2
| | - Wenbin Fu
- Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510120.,Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China, 510000
| | - Guoqing Liu
- Institute of Cardiovascular Science, Peking University Health Science Center, Beijing, P.R. China, 100083
| | - Philip W Connelly
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8
| | - Margaret L Rand
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, M5G 1X8
| | - Khosrow Adeli
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Program in Molecular Structure & Function, The Hospital for Sick Children, Toronto, ON, Canada, M5G 1X8
| | - John Freedman
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8.,Department of Medicine, University of Toronto, Toronto, ON, Canada, M5S 1A1
| | - Jeffrey E Lee
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1
| | - Patrick Tso
- Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA, 45219
| | - Patrizia Marchese
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA, 92037
| | - W Sean Davidson
- Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA, 45219
| | - Shaun P Jackson
- Heart Research Institute, and Charles Perkins Centre, The University of Sydney, Camperdown, Australia, 2006.,Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA, 92037
| | - Cheng Zhu
- Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA, 30332.,Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA, 30332.,Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA, 30332
| | - Zaverio M Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA, 92037
| | - Heyu Ni
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, M5S 1A1. .,Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Toronto Platelet Immunobiology Group, Toronto, ON, Canada, M5B 1W8. .,Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, M5G 2M1. .,Department of Medicine, University of Toronto, Toronto, ON, Canada, M5S 1A1. .,Department of Physiology, University of Toronto, Toronto, ON, Canada, M5S 1A1.
| |
Collapse
|
11
|
|
12
|
Ikeda Y, Handa M, Kamata T, Kawano K, Kawai Y, Watanabe K, Kawakami K, Sakai K, Fukuyama M, Itagaki I, Yoshioka A, Ruggeri ZM. Transmembrane Calcium Influx Associated with von Willebrand Factor Binding to GP Ib in the Initiation of Shear-Induced Platelet Aggregation. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1651640] [Citation(s) in RCA: 97] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe found that the binding of multimeric vWF to GP Ib under a shear force of 108 dynes/cm2 resulted in the transmembrane flux of Ca2+ ions with a two-to three-fold increase in their intracellular concentration ([Ca2+]i). The blockage of this event, obtained by inhibiting the vWF-GP Ib interaction, suppressed aggregation. In contrast, the blockage of vWF binding to GP IIb-IIIa, as well as the prevention of activation caused by increased intracellular cAMP levels, inhibited aggregation but had no significant effect on [Ca2+]i increase. A monomeric recombinant fragment of vWF containing the GP Ib-binding domain of the molecule (residues 445-733) prevented all effects mediated by multimeric vWF but, by itself, failed to support the increase in [Ca2+]i and aggregation. These results suggest that the binding of multimeric vWF to GP Ib initiates platelets aggregation induced by high shear stress by mediating a transmembrane flux of Ca2+ ions, perhaps through a receptor-dependent calcium channel. The increase in [Ca2+]i may act as an intracellular message and cause the activation of GP IIb-IIIa; the latter receptor then binds vWF and mediates irreversible aggregation.
Collapse
Affiliation(s)
- Yasuo Ikeda
- The Departments of Hematology and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Makoto Handa
- The Departments of Hematology and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Tetsuji Kamata
- The Departments of Hematology and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Koichi Kawano
- The Departments of Hematology and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Yohko Kawai
- The Departments of Hematology and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kiyoaki Watanabe
- The Departments of Hematology and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Keiko Kawakami
- The Department of Chemical Engineering, Waseda University, Tokyo, Japan
| | - Kiyotaka Sakai
- The Department of Chemical Engineering, Waseda University, Tokyo, Japan
| | - Mayumi Fukuyama
- The Basic Research Institute, Toray Industries Inc., Kanagawa, Japan
| | - Ichiro Itagaki
- The Basic Research Institute, Toray Industries Inc., Kanagawa, Japan
| | - Akira Yoshioka
- The Department of Pediatrics, Nara Medical School, Nara, Japan
| | - Zaverio M Ruggeri
- The Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine and Committee on Vascular Biology, The Scripps Research Institute, La Jolla, California, USA
| |
Collapse
|
13
|
Wahlberg TB, Blombäck M, Ruggeri ZM. Differences Between Heterozygous Dominant and Recessive von Willebrand’s Disease Type I Expressed by Bleeding Symptoms and Combinations of Factor VIII Variables. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1665330] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThree families with von Willebrand’s disease (vWd) type I were investigated. A reliable identification of healthy and diseased individuals was achieved by number of bleeding symptoms, assays of bleeding time, FVIII:C (one stage and two stage), VIIIR: Ag (EIA) and ristocetin cofactor. The diagnoses - vWd or non-vWd were confirmed by laboratory indices based on predictive values of positive and negative tests, also including VIIIR: Ag (IRMA and RIA). The last mentioned two variables did not contribute to significantly better identification of vWd versus health. The best single test variable for this purpose was ristocetin cofactor. One vWd family had significantly higher levels of ristocetin cofactor and shorter bleeding time than the other two vWd families and is probably the typical example of a family transmitting classical severe vWd.
Collapse
Affiliation(s)
- T B Wahlberg
- The Dept of Blood Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden
| | - M Blombäck
- The Dept of Blood Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden
| | - Z M Ruggeri
- The Depts of Immunology and of Basic and Clinical Research, Scripps Clinic and Research Foundation, La Jolla, California, U.S.A
| |
Collapse
|
14
|
Federici AB, Mannucci PM, Stabile F, Canciani MT, Di Rocco N, Miyata S, Ware J, Ruggeri ZM. A Type 2b von Willebrand Disease Mutation (lle546→Val) Associated with an Unusual Phenotype. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657699] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryType 2B von Willebrand disease (vWD) is typically characterized by enhanced ristocetin-induced platelet aggregation (RIPA) caused by increased von Willebrand factor (vWF) affinity for platelets. Furthermore, absence of larger vWF multimers in plasma is characteristic of the originally described type IIB patients, now considered a subgroup of type 2B. We describe here three affected members of a family presenting with prolonged bleeding time, thrombocytopenia, markedly enhanced RIPA and spontaneous platelet aggregation, but normal plasma vWF antigen and ristocetin cofactor activity. Larger plasma vWF multimers, albeit decreased, were present in relatively greater proportion than in other type IIB patients. Genetic studies performed in two of these patients resulted in the identification of a previously unreported A→G transition at nucleotide 4175 in the sequence of the pre-pro-vWF cDNA, corresponding to the substitution Ile546→Val in the mature vWF subunit. This mutation appears to be responsible for an unusual type 2B phenotype, with greater enhancement of the vWF platelet interaction than in typical cases but partial preservation of the larger vWF multimers in plasma.
Collapse
Affiliation(s)
- A B Federici
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milano, Italy
| | - P M Mannucci
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milano, Italy
| | - F Stabile
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milano, Italy
| | - M T Canciani
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milano, Italy
| | - N Di Rocco
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milano, Italy
| | - S Miyata
- The Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine and Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
| | - J Ware
- The Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine and Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
| | - Z M Ruggeri
- The Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine and Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
| |
Collapse
|
15
|
Pareti FI, Cattaneo M, Carpinelli L, Zighetti ML, Bressi C, Mannuccio Mannucci P, Ruggeri ZM. Evaluation of the Abnormal Platelet Function in von Willebrand Disease by the Blood Filtration Test. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650600] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have evaluated platelet function in different subtypes of von Willebrand disease (vWD) by pushing blood through the capillarysized channels of a glass filter. Patients, including those with type IIB vWD, showed lower than normal platelet retention and increased cumulative number of blood drops passing through the filter as a function of time. In contrast, shear-induced platelet aggregation, measured in the cone-and-plate viscometer, was paradoxically increased in type IIB patients. Treatment with l-desamino-8-D-arginine vasopressin (DDAVP) tended to normalize the filter test in patients with type I-platelet normal and type I-platelet low vWD, but infusion of a factor VUI/von Willebrand factor (vWF) concentrate lacking the largest vWF multimers was without effect in type 3 patients. Experiments with specific monoclonal antibodies demonstrated that the A1 and A3 domains of vWF, as well as the glycoproteins Ibα and Ilb-IIIa on platelets, are required for platelet retention in the filter. Thus, the test may reflect vWF function with regard to both platelet adhesion and aggregation under high shear stress, and provide relevant information on mechanisms involved in primary hemostasis.
Collapse
Affiliation(s)
- Francesco I Pareti
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
| | - Marco Cattaneo
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
| | - Luca Carpinelli
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
| | - Maddalena L Zighetti
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
| | - Caterina Bressi
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
| | - Pier Mannuccio Mannucci
- The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
| | - Zaverio M Ruggeri
- The Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Departments of Molecular and Experimental Medicine and of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
| |
Collapse
|
16
|
Dardik R, Ruggeri ZM, Savion N, Gitel S, Martinowitz U, Chu V, Varon D. Platelet Aggregation on Extracellular Matrix: Effect of a Recombinant GPIb-Binding Fragment of von Willebrand Factor. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649616] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryPlatelets in whole blood incubated on extracellular matrix (ECM) produced by bovine corneal endothelial cells under oscillatory flow conditions demonstrate extensive aggregate formation. Since both platelet-subendothelium and platelet-platelet interactions are mediated by von Willebrand factor (vWF), we used this system to examine the effect of a recombinant GPIb-binding fragment of vWF (designated RG12986), comprising residues 445-733 of the native vWF subunit, on platelet reactivity with ECM. The seven cysteines present in the RG12986 fragment were reduced and alkylated in order to achieve a monomeric conformation. The recombinant vWF fragment binds to unstimulated platelets in the absence of exogenous modulators. When added to platelet-rich plasma, it inhibits ristocetin-induced platelet agglutination. Binding of 51Cr-labeled platelets in reconstituted whole blood to ECM was inhibited by RG12986 in a dose dependent and saturable manner, with IC50 of 4 μM and maximal inhibition (about 70%) at 6 μM. Scanning electron microscope (SEM) analysis showed that addition of RG12986 to whole blood significantly inhibited platelet aggregation on ECM. The extent of inhibition observed with RG12986 at a final concentration of 4 μM was similar to that obtained with the cell adhesion peptide RGDS at the concentration of 0.1 mM. The ability of the RG12986 fragment to inhibit platelet aggregation on ECM is in agreement with the concept that blockade of vWF-GPIb interaction may inhibit further events leading to activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex and subsequent thrombus formation.
Collapse
Affiliation(s)
- R Dardik
- National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
| | - Z M Ruggeri
- Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine and Committee on Vascular Biology, The Scripps Research Institute, La Jolla, California, USA
| | - N Savion
- Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel Aviv University, Israel
| | - S Gitel
- National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
| | - U Martinowitz
- National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
| | - V Chu
- Rhone-Poulenc Rorer Central Research, King of Prussia, Pennsylvania, USA
| | - D Varon
- National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel
| |
Collapse
|
17
|
Affiliation(s)
- Zaverio M Ruggeri
- Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine and Committee on Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
| |
Collapse
|
18
|
Affiliation(s)
- Zaverio M Ruggeri
- The Roon Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Thrombosis and Hemostasis, Department of Molecular and Experimental Medicine and Committee on Vascular Biology, The Scripps Research Institute, La Jolla, CA, U.S. A
| | - Jerry Ware
- The Roon Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Thrombosis and Hemostasis, Department of Molecular and Experimental Medicine and Committee on Vascular Biology, The Scripps Research Institute, La Jolla, CA, U.S. A
| |
Collapse
|
19
|
Azuma H, Sugimoto M, Ruggeri ZM, Ware J. A Role for von Willebrand Factor Proline Residues 702-704 in Ristocetin-Mediated Binding to Platelet Glycoprotein Ib. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1651578] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryMutant domains of von Willebrand factor (vWF) were constructed to determine the effects of altering net charge, and presumably conformation, within a peptide sequence (residues 694-708) previously shown to be involved in the platelet receptor glycoprotein (GP) Ib binding function of vWF. Non-conservative substitutions replaced a triplet of proline residues (proline702–704) with either a triplet of arginine (positively-charged) or aspartic acid (negatively-charged) residues. After establishing stable CHO cell transformants, we observed the secretion of covalently-linked dimeric molecules analogous to a domain with native sequence. Functional assays using immunopurified molecules revealed that the ristocetin-dependent binding to GP Ib was abolished with both charge mutants. However, in the absence of disulfide-bond dependent conformation both mutant molecules and the molecule with native sequence interacted with GP Ib. The results demonstrate that vWF proline702–704 are important for the ristocetin-mediated interaction between vWF and GP Ib, but are not essential residues of the GP Ib binding site within vWF.
Collapse
Affiliation(s)
- Hiroyuki Azuma
- The Roon Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
| | - Mitsuhiko Sugimoto
- The Roon Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
| | - Zaverio M Ruggeri
- The Roon Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
| | - Jerry Ware
- The Roon Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
| |
Collapse
|
20
|
Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic Detection of von Willebrand Factor Multimers in Agarose Gels and on Nitrocellulose Membranes. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1645215] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryTwo methods for visualization of vWf multimers were compared with respect to sensitivity and detection of normal vWf and vWd variants IIA, IIB, IIC, IID, HE, and HE Autoradiography and luminography after electrotransfer of vWf multimers onto nitrocellulose showed comparable sensitivity with vWf: Ag detectable after 1:500 dilution of normal plasma. The least sensitive method was luminography in agarose gels with vWf: Ag detectable after 1:300dilution of normal plasma. No difference existed in the banding patterns of plasmas from patients with variant vWd.
Collapse
Affiliation(s)
- U Budde
- The Blood Transfusion Service AK Harburg, Hamburg, FRG
| | | | - H Plendl
- The Dept. of Human Genetics, University Clinic, Kiel, FRG
| | - J Dent
- The Scripps Clinic and Research Foundation, La Jolla, CA, USA
| | - Z M Ruggeri
- The Scripps Clinic and Research Foundation, La Jolla, CA, USA
| | - T S Zimmerman
- The Scripps Clinic and Research Foundation, La Jolla, CA, USA
| |
Collapse
|
21
|
Ginsburg D, Bockenstedt PL, Allen EA, Fox DA, Foster PA, Ruggeri ZM, Zimmerman TS, Montgomery RR, Bahou WF, Johnson TA, Yang AY. Fine Mapping of Monoclonal Antibody Epitopes on Human von Willebrand Factor Using a Recombinant Peptide Library. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1648400] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA recombinant human von Willebrand factor (vWF) cDNA fragment library was constructed in λgtll for the localization of anti-vWF monoclonal antibody epitopes. Twelve of 21 monoclonal antibodies screened identified epitopes expressed in λgtll as β-galactosidase fusion proteins. By sequence analysis, these antigenic determinants were localized to segments ranging from 17 to 105 amino acids in length. Four epitopes apparently shared by more than one antibody were identified, suggesting the presence of immuno-dominant epitopes within vWF. Monoclonal antibody C3, which blocks factor VIII (FVIII) binding to vWF, bound to the same epitope previously identified by a second monoclonal antibody which also blocks this function, suggesting that this region may be at or near the vWF/FVIII binding domain. Three antibodies recognize the same region within the vWF A2 repeat. Mutations near this region appear to be responsible for Type IIA von Willebrand’s disease. The co-localization of these antibodies suggests that this domain might be exposed on the surface of vWF, consistent with its apparent increased sensitivity to plasma proteases.
Collapse
Affiliation(s)
- David Ginsburg
- The Howard Hughes Medical Institute and Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA
- The Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Paula L Bockenstedt
- The Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Elizabeth A Allen
- The Howard Hughes Medical Institute and Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA
| | - David A Fox
- The Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Paul A Foster
- The Department of Molecular and Experimental Medicine and Committee on Vascular Biology, Scripps Clinic and Research Foundation, La Jolla, CA, USA
| | - Zaverio M Ruggeri
- The Department of Molecular and Experimental Medicine and Committee on Vascular Biology, Scripps Clinic and Research Foundation, La Jolla, CA, USA
| | - Theodore S Zimmerman
- The Department of Molecular and Experimental Medicine and Committee on Vascular Biology, Scripps Clinic and Research Foundation, La Jolla, CA, USA
| | - Robert R Montgomery
- The Blood Center of Southeastern Wisconsin and Medical College of Wisconsin, Milwaukee, WI, USA
| | - Wadie F Bahou
- The Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Timothy A Johnson
- The Howard Hughes Medical Institute and Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Angela Y Yang
- The Howard Hughes Medical Institute and Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA
| |
Collapse
|
22
|
Lombardi M, Marchese P, Ferrara D, Ruggeri ZM, Foglieni C. Perivascular Adipose Tissue and Thrombus Formation: ex-vivo Study on Internal Mammary Artery. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Zilberman-Rudenko J, Deguchi H, Orje J, Wyseure T, Mosnier LO, McCarty OJ, Ruggeri ZM, Griffin JH. Abstract 148: Cardiac Myosin Promotes Thrombin Generation and Attenuates Tissue Plasminogen Activator-induced Plasma Clot Lysis. Arterioscler Thromb Vasc Biol 2018. [DOI: 10.1161/atvb.38.suppl_1.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Recently we discovered that skeletal muscle myosin, which is in the same family as cardiac myosin, exerts prothrombotic effects by binding factor Xa and enhancing prothrombin activation in the presence of factor Va. Thus, we tested the influence of cardiac myosin on thrombus formation and fibrinolysis. Studies of the effects of cardiac myosin on thrombogenesis
ex vivo
using fresh human flowing blood showed that perfusion of blood over cardiac myosin-coated surfaces at 300 s
-1
shear rate caused extensive fibrin deposition. Addition of cardiac myosin to blood also promoted the thrombotic responses of human blood flowing over collagen-coated surfaces, evidence of myosin’s thrombogenicity. Further studies showed that cardiac myosin enhanced thrombin generation in whole blood, platelet rich plasma and platelet poor plasma, indicating that myosin promotes thrombin generation in plasma primarily independently of platelets or other blood cell components. In a purified system composed of factor Xa, factor Va, prothrombin and calcium ions, cardiac myosin greatly enhanced prothrombinase activity. Experiments using Gla-domainless factor Xa showed that the Gla domain of factor Xa was not required for cardiac myosin’s prothrombinase enhancement in contrast to phospholipid-enhanced prothrombinase activity which requires that Gla domain. In studies of tissue plasminogen activator (tPA)-induced plasma clot lysis, increasing concentrations of cardiac myosin attenuated tPA-mediated clot lysis. The ability of cardiac myosin to inhibit tPA-induced plasma clot lysis was ablated in the presence of the carboxypeptidase inhibitor from potatoes, an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI). Clot lysis assays using TAFI-deficient plasma confirmed the requirement for TAFI for the antifibrinolytic action of cardiac myosin. We hypothesize that cardiac myosin-dependent thrombin generation increases TAFI activation and subsequent inhibition of clot lysis. In summary, here we show that cardiac myosin is both procoagulant and anti-fibrinolytic due to its ability to bind factor Xa and strongly promote thrombin generation. This raises new questions about potential procoagulant functions for cardiac myosin in coronary health and disease.
Collapse
|
24
|
Kossmann S, Lagrange J, Jäckel S, Jurk K, Ehlken M, Schönfelder T, Weihert Y, Knorr M, Brandt M, Xia N, Li H, Daiber A, Oelze M, Reinhardt C, Lackner K, Gruber A, Monia B, Karbach SH, Walter U, Ruggeri ZM, Renné T, Ruf W, Münzel T, Wenzel P. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. Sci Transl Med 2018; 9:9/375/eaah4923. [PMID: 28148841 DOI: 10.1126/scitranslmed.aah4923] [Citation(s) in RCA: 73] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Revised: 07/05/2016] [Accepted: 12/12/2016] [Indexed: 01/05/2023]
Abstract
Multicellular interactions of platelets, leukocytes, and the blood vessel wall support coagulation and precipitate arterial and venous thrombosis. High levels of angiotensin II cause arterial hypertension by a complex vascular inflammatory pathway that requires leukocyte recruitment and reactive oxygen species production and is followed by vascular dysfunction. We delineate a previously undescribed, proinflammatory coagulation-vascular circuit that is a major regulator of vascular tone, blood pressure, and endothelial function. In mice with angiotensin II-induced hypertension, tissue factor was up-regulated, as was thrombin-dependent endothelial cell vascular cellular adhesion molecule 1 expression and integrin αMβ2- and platelet-dependent leukocyte adhesion to arterial vessels. The resulting vascular inflammation and dysfunction was mediated by activation of thrombin-driven factor XI (FXI) feedback, independent of factor XII. The FXI receptor glycoprotein Ibα on platelets was required for this thrombin feedback activation in angiotensin II-infused mice. Inhibition of FXI synthesis with an antisense oligonucleotide was sufficient to prevent thrombin propagation on platelets, vascular leukocyte infiltration, angiotensin II-induced endothelial dysfunction, and arterial hypertension in mice and rats. Antisense oligonucleotide against FXI also reduced the increased blood pressure and attenuated vascular and kidney dysfunction in rats with established arterial hypertension. Further, platelet-localized thrombin generation was amplified in an FXI-dependent manner in patients with uncontrolled arterial hypertension, suggesting that platelet-localized thrombin generation may serve as an inflammatory marker of high blood pressure. Our results outline a coagulation-inflammation circuit that promotes vascular dysfunction, and highlight the possible utility of FXI-targeted anticoagulants in treating hypertension, beyond their application as antithrombotic agents in cardiovascular disease.
Collapse
Affiliation(s)
- Sabine Kossmann
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.,Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Jeremy Lagrange
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
| | - Sven Jäckel
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
| | - Kerstin Jurk
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
| | - Moritz Ehlken
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.,Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Tanja Schönfelder
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
| | - Yvonne Weihert
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Maike Knorr
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Moritz Brandt
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Ning Xia
- Department of Pharmacology, University Medical Center Mainz, 55131 Mainz, Germany
| | - Huige Li
- Department of Pharmacology, University Medical Center Mainz, 55131 Mainz, Germany
| | - Andreas Daiber
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Matthias Oelze
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Christoph Reinhardt
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
| | - Karl Lackner
- Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, 55131 Mainz, Germany
| | - Andras Gruber
- Department of Biomedical Engineering, Oregon Health and Science University, 3303 Southwest Bond Avenue, CH13B, Portland, OR 97239, USA.,Aronora Inc., 4640 Southwest Macadam Avenue, Suite 200A, Portland, OR 97239, USA
| | - Brett Monia
- Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA
| | - Susanne H Karbach
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany
| | - Ulrich Walter
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
| | - Zaverio M Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Thomas Renné
- Department of Molecular Medicine and Surgery, L1:00, Karolinska Institutet, SE-171 71 Stockholm, Sweden.,Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
| | - Wolfram Ruf
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.,Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.,DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, University Medical Center Mainz, 55131 Mainz, Germany
| | - Thomas Münzel
- Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany.,DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, University Medical Center Mainz, 55131 Mainz, Germany
| | - Philip Wenzel
- Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany. .,Center for Cardiology, Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany.,DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, University Medical Center Mainz, 55131 Mainz, Germany
| |
Collapse
|
25
|
Dütting S, Gaits-Iacovoni F, Stegner D, Popp M, Antkowiak A, van Eeuwijk JMM, Nurden P, Stritt S, Heib T, Aurbach K, Angay O, Cherpokova D, Heinz N, Baig AA, Gorelashvili MG, Gerner F, Heinze KG, Ware J, Krohne G, Ruggeri ZM, Nurden AT, Schulze H, Modlich U, Pleines I, Brakebusch C, Nieswandt B. A Cdc42/RhoA regulatory circuit downstream of glycoprotein Ib guides transendothelial platelet biogenesis. Nat Commun 2017. [PMID: 28643773 PMCID: PMC5481742 DOI: 10.1038/ncomms15838] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Blood platelets are produced by large bone marrow (BM) precursor cells, megakaryocytes (MKs), which extend cytoplasmic protrusions (proplatelets) into BM sinusoids. The molecular cues that control MK polarization towards sinusoids and limit transendothelial crossing to proplatelets remain unknown. Here, we show that the small GTPases Cdc42 and RhoA act as a regulatory circuit downstream of the MK-specific mechanoreceptor GPIb to coordinate polarized transendothelial platelet biogenesis. Functional deficiency of either GPIb or Cdc42 impairs transendothelial proplatelet formation. In the absence of RhoA, increased Cdc42 activity and MK hyperpolarization triggers GPIb-dependent transmigration of entire MKs into BM sinusoids. These findings position Cdc42 (go-signal) and RhoA (stop-signal) at the centre of a molecular checkpoint downstream of GPIb that controls transendothelial platelet biogenesis. Our results may open new avenues for the treatment of platelet production disorders and help to explain the thrombocytopenia in patients with Bernard-Soulier syndrome, a bleeding disorder caused by defects in GPIb-IX-V.
Collapse
Affiliation(s)
- Sebastian Dütting
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Frederique Gaits-Iacovoni
- INSERM UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires-I2MC, UMR1048, Institut National de la Santé et de la Recherche Médicale, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse Cedex 4, France
| | - David Stegner
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Michael Popp
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Adrien Antkowiak
- INSERM UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires-I2MC, UMR1048, Institut National de la Santé et de la Recherche Médicale, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse Cedex 4, France
| | - Judith M M van Eeuwijk
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Paquita Nurden
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Institut Hospitalo-Universitaire LIRYC, Plateforme Technologique d'Innovation Biomédicale, Hôpital Xavier Arnozan, Avenue du Haut Lévêque, 33604 Pessac, France
| | - Simon Stritt
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Tobias Heib
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Katja Aurbach
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Oguzhan Angay
- Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Deya Cherpokova
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Niels Heinz
- Research Group for Gene Modification in Stem Cells, LOEWE Center for Cell and Gene Therapy Frankfurt/Main and the Paul-Ehrlich-Institute, Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany
| | - Ayesha A Baig
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Maximilian G Gorelashvili
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Frank Gerner
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Katrin G Heinze
- Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Jerry Ware
- Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, Arkansass 72205, USA
| | - Georg Krohne
- Biocenter, University of Würzburg, Am Hubland, 97074 Würzburg, Germany
| | - Zaverio M Ruggeri
- Department of Molecular Medicine, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, California 92037, USA
| | - Alan T Nurden
- Institut Hospitalo-Universitaire LIRYC, Plateforme Technologique d'Innovation Biomédicale, Hôpital Xavier Arnozan, Avenue du Haut Lévêque, 33604 Pessac, France
| | - Harald Schulze
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Ute Modlich
- Research Group for Gene Modification in Stem Cells, LOEWE Center for Cell and Gene Therapy Frankfurt/Main and the Paul-Ehrlich-Institute, Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany
| | - Irina Pleines
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| | - Cord Brakebusch
- BRIC, Biomedical Institute, University of Copenhagen, Nørregade 10, 1165 Copenhagen, Denmark
| | - Bernhard Nieswandt
- Institute of Experimental Biomedicine, University Hospital and University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.,Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
| |
Collapse
|
26
|
Rothmeier AS, Marchese P, Langer F, Kamikubo Y, Schaffner F, Cantor J, Ginsberg MH, Ruggeri ZM, Ruf W. Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking. Arterioscler Thromb Vasc Biol 2017; 37:1323-1331. [PMID: 28495929 DOI: 10.1161/atvbaha.117.309315] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Accepted: 05/01/2017] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Coagulation initiation by tissue factor (TF) is regulated by cellular inhibitors, cell surface availability of procoagulant phosphatidylserine, and thiol-disulfide exchange. How these mechanisms contribute to keeping TF in a noncoagulant state and to generating prothrombotic TF remain incompletely understood. APPROACH AND RESULTS Here, we study the activation of TF in primary macrophages by a combination of pharmacological, genetic, and biochemical approaches. We demonstrate that primed macrophages effectively control TF cell surface activity by receptor internalization. After cell injury, ATP signals through the purinergic receptor P2rx7 induce release of TF+ microvesicles. TF cell surface availability for release onto microvesicles is regulated by the GTPase arf6 associated with integrin α4β1. Furthermore, microvesicles proteome analysis identifies activation of Gαi2 as a participating factor in the release of microvesicles with prothrombotic activity in flowing blood. ATP not only prevents TF and phosphatidylserine internalization but also induces TF conversion to a conformation with high affinity for its ligand, coagulation factor VII. Although inhibition of dynamin-dependent internalization also exposes outer membrane procoagulant phosphatidylserine, the resulting TF+ microvesicles distinctly lack protein disulfide isomerase and high affinity TF and fail to produce fibrin strands typical for microvesicles generated by thrombo-inflammatory P2rx7 activation. CONCLUSIONS These data show that procoagulant phospholipid exposure is not sufficient and that TF affinity maturation is required to generate prothrombotic microvesicles from a variety of cell types. These findings are significant for understanding TF-initiated thrombosis and should be considered in designing functional microvesicles-based diagnostic approaches.
Collapse
Affiliation(s)
- Andrea S Rothmeier
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Patrizia Marchese
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Florian Langer
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Yuichi Kamikubo
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Florence Schaffner
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Joseph Cantor
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Mark H Ginsberg
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Zaverio M Ruggeri
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.)
| | - Wolfram Ruf
- From the Department of Immunology and Microbiology (A.S.R., F.S., W.R.) and Molecular Medicine (P.M., Y.K., Z.M.R.), The Scripps Research Institute, La Jolla, CA; II. Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany (F.L.); Department of Medicine, University of California San Diego, La Jolla (J.C., M.H.G.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.).
| |
Collapse
|
27
|
Weber MR, Zuka M, Lorger M, Tschan M, Torbett BE, Zijlstra A, Quigley JP, Staflin K, Eliceiri BP, Krueger JS, Marchese P, Ruggeri ZM, Felding BH. Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream. Thromb Res 2017; 140 Suppl 1:S27-36. [PMID: 27067975 DOI: 10.1016/s0049-3848(16)30095-0] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Metastasis is the main cause of death in cancer patients, and understanding mechanisms that control tumor cell dissemination may lead to improved therapy. Tumor cell adhesion receptors contribute to cancer spreading. We noted earlier that tumor cells can expressing the adhesion receptor integrin αvβ3 in distinct states of activation, and found that cells which metastasize from the blood stream express it in a constitutively high affinity form. Here, we analyzed steps of the metastatic cascade in vivo and asked, when and how the affinity state of integrin αvβ3 confers a critical advantage to cancer spreading. Following tumor cells by real time PCR, non-invasive bioluminescence imaging, intravital microscopy and histology allowed us to identify tumor cell extravasation from the blood stream as a rate-limiting step supported by high affinity αvβ3. Successful transendothelial migration depended on cooperation between tumor cells and platelets involving the high affinity tumor cell integrin and release of platelet granules. Thus, this study identifies the high affinity conformer of integrin αvβ3 and its interaction with platelets as critical for early steps during hematogenous metastasis and target for prevention of metastatic disease.
Collapse
Affiliation(s)
- Martin R Weber
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Masahiko Zuka
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Mihaela Lorger
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Mario Tschan
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Bruce E Torbett
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Andries Zijlstra
- Department of Cell Biology, The Scripps Research Institute, La Jolla, California, USA
| | - James P Quigley
- Department of Cell Biology, The Scripps Research Institute, La Jolla, California, USA
| | - Karin Staflin
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Brian P Eliceiri
- Department of Surgery, University of California San Diego, San Diego, CA 92103, USA
| | - Joseph S Krueger
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Patrizia Marchese
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Zaverio M Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
| | - Brunhilde H Felding
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA; Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California, USA.
| |
Collapse
|
28
|
Horton LE, Sullivan BM, Garry RF, Grant DS, Aiolfi R, Ruggeri ZM, Oldstone MB. Dysfunctional Platelet Aggregation in Patients with Acute Lassa Fever. Open Forum Infect Dis 2017. [DOI: 10.1093/ofid/ofx163.460] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Kaplan ZS, Zarpellon A, Alwis I, Yuan Y, McFadyen J, Ghasemzadeh M, Schoenwaelder SM, Ruggeri ZM, Jackson SP. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nat Commun 2015. [PMID: 26204458 DOI: 10.1038/ncomms8835] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Thrombin is a central regulator of leukocyte recruitment and inflammation at sites of vascular injury, a function thought to involve primarily endothelial PAR cleavage. Here we demonstrate the existence of a distinct leukocyte-trafficking mechanism regulated by components of the haemostatic system, including platelet PAR4, GPIbα and fibrin. Utilizing a mouse endothelial injury model we show that thrombin cleavage of platelet PAR4 promotes leukocyte recruitment to sites of vascular injury. This process is negatively regulated by GPIbα, as seen in mice with abrogated thrombin-platelet GPIbα binding (hGPIbα(D277N)). In addition, we demonstrate that fibrin limits leukocyte trafficking by forming a physical barrier to intravascular leukocyte migration. These studies demonstrate a distinct 'checkpoint' mechanism of leukocyte trafficking involving balanced thrombin interactions with PAR4, GPIbα and fibrin. Dysregulation of this checkpoint mechanism is likely to contribute to the development of thromboinflammatory disorders.
Collapse
Affiliation(s)
- Zane S Kaplan
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
| | - Alessandro Zarpellon
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
| | - Imala Alwis
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.,Heart Research Institute &Charles Perkins Centre, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Yuping Yuan
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
| | - James McFadyen
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
| | - Mehran Ghasemzadeh
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.,Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
| | - Simone M Schoenwaelder
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.,Heart Research Institute &Charles Perkins Centre, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Zaverio M Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
| | - Shaun P Jackson
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.,Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.,Heart Research Institute &Charles Perkins Centre, The University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
30
|
Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, Fiocchi A, Vacca M, Aiolfi R, Sammicheli S, Mainetti M, Cataudella T, Raimondi A, Gonzalez-Aseguinolaza G, Protzer U, Ruggeri ZM, Chisari FV, Isogawa M, Sitia G, Iannacone M. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 2015. [PMID: 25892224 DOI: 10.1016/j.cell.2015.03.005.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Effector CD8(+) T cells (CD8 TE) play a key role during hepatotropic viral infections. Here, we used advanced imaging in mouse models of hepatitis B virus (HBV) pathogenesis to understand the mechanisms whereby these cells home to the liver, recognize antigens, and deploy effector functions. We show that circulating CD8 TE arrest within liver sinusoids by docking onto platelets previously adhered to sinusoidal hyaluronan via CD44. After the initial arrest, CD8 TE actively crawl along liver sinusoids and probe sub-sinusoidal hepatocytes for the presence of antigens by extending cytoplasmic protrusions through endothelial fenestrae. Hepatocellular antigen recognition triggers effector functions in a diapedesis-independent manner and is inhibited by the processes of sinusoidal defenestration and capillarization that characterize liver fibrosis. These findings reveal the dynamic behavior whereby CD8 TE control hepatotropic pathogens and suggest how liver fibrosis might reduce CD8 TE immune surveillance toward infected or transformed hepatocytes.
Collapse
Affiliation(s)
- Luca G Guidotti
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA.
| | - Donato Inverso
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy
| | - Laura Sironi
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Physics, University of Milano Bicocca, 20126 Milan, Italy
| | - Pietro Di Lucia
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Jessica Fioravanti
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Lucia Ganzer
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Physics, University of Milano Bicocca, 20126 Milan, Italy
| | - Amleto Fiocchi
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Maurizio Vacca
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Roberto Aiolfi
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy
| | - Stefano Sammicheli
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Marta Mainetti
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Tiziana Cataudella
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Andrea Raimondi
- Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | | | - Ulrike Protzer
- Institute of Virology, Technical University of Munich, 81675 Munich, Germany
| | - Zaverio M Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Francis V Chisari
- Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Masanori Isogawa
- Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Giovanni Sitia
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Matteo Iannacone
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy; Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
| |
Collapse
|
31
|
Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, Fiocchi A, Vacca M, Aiolfi R, Sammicheli S, Mainetti M, Cataudella T, Raimondi A, Gonzalez-Aseguinolaza G, Protzer U, Ruggeri ZM, Chisari FV, Isogawa M, Sitia G, Iannacone M. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 2015; 161:486-500. [PMID: 25892224 DOI: 10.1016/j.cell.2015.03.005] [Citation(s) in RCA: 207] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Revised: 12/18/2014] [Accepted: 02/24/2015] [Indexed: 02/06/2023]
Abstract
Effector CD8(+) T cells (CD8 TE) play a key role during hepatotropic viral infections. Here, we used advanced imaging in mouse models of hepatitis B virus (HBV) pathogenesis to understand the mechanisms whereby these cells home to the liver, recognize antigens, and deploy effector functions. We show that circulating CD8 TE arrest within liver sinusoids by docking onto platelets previously adhered to sinusoidal hyaluronan via CD44. After the initial arrest, CD8 TE actively crawl along liver sinusoids and probe sub-sinusoidal hepatocytes for the presence of antigens by extending cytoplasmic protrusions through endothelial fenestrae. Hepatocellular antigen recognition triggers effector functions in a diapedesis-independent manner and is inhibited by the processes of sinusoidal defenestration and capillarization that characterize liver fibrosis. These findings reveal the dynamic behavior whereby CD8 TE control hepatotropic pathogens and suggest how liver fibrosis might reduce CD8 TE immune surveillance toward infected or transformed hepatocytes.
Collapse
Affiliation(s)
- Luca G Guidotti
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA.
| | - Donato Inverso
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy
| | - Laura Sironi
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Physics, University of Milano Bicocca, 20126 Milan, Italy
| | - Pietro Di Lucia
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Jessica Fioravanti
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Lucia Ganzer
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Physics, University of Milano Bicocca, 20126 Milan, Italy
| | - Amleto Fiocchi
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Maurizio Vacca
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Roberto Aiolfi
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy
| | - Stefano Sammicheli
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Marta Mainetti
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Tiziana Cataudella
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Andrea Raimondi
- Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | | | - Ulrike Protzer
- Institute of Virology, Technical University of Munich, 81675 Munich, Germany
| | - Zaverio M Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Francis V Chisari
- Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Masanori Isogawa
- Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Giovanni Sitia
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Matteo Iannacone
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy; Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
| |
Collapse
|
32
|
Rothmeier AS, Marchese P, Petrich BG, Furlan-Freguia C, Ginsberg MH, Ruggeri ZM, Ruf W. Caspase-1-mediated pathway promotes generation of thromboinflammatory microparticles. J Clin Invest 2015; 125:1471-84. [PMID: 25705884 DOI: 10.1172/jci79329] [Citation(s) in RCA: 85] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Accepted: 01/09/2015] [Indexed: 12/30/2022] Open
Abstract
Extracellular ATP is a signal of tissue damage and induces macrophage responses that amplify inflammation and coagulation. Here we demonstrate that ATP signaling through macrophage P2X7 receptors uncouples the thioredoxin (TRX)/TRX reductase (TRXR) system and activates the inflammasome through endosome-generated ROS. TRXR and inflammasome activity promoted filopodia formation, cellular release of reduced TRX, and generation of extracellular thiol pathway-dependent, procoagulant microparticles (MPs). Additionally, inflammasome-induced activation of an intracellular caspase-1/calpain cysteine protease cascade degraded filamin, thereby severing bonds between the cytoskeleton and tissue factor (TF), the cell surface receptor responsible for coagulation activation. This cascade enabled TF trafficking from rafts to filopodia and ultimately onto phosphatidylserine-positive, highly procoagulant MPs. Furthermore, caspase-1 specifically facilitated cell surface actin exposure, which was required for the final release of highly procoagulant MPs from filopodia. Together, the results of this study delineate a thromboinflammatory pathway and suggest that components of this pathway have potential as pharmacological targets to simultaneously attenuate inflammation and innate immune cell-induced thrombosis.
Collapse
|
33
|
Ruggeri ZM, Mendolicchio GL. Interaction of von Willebrand factor with platelets and the vessel wall. Hamostaseologie 2015; 35:211-24. [PMID: 25612915 DOI: 10.5482/hamo-14-12-0081] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Accepted: 12/09/2014] [Indexed: 01/19/2023] Open
Abstract
The initiation of thrombus formation at sites of vascular injury to secure haemostasis after tissue trauma requires the interaction of surface-exposed von Willebrand factor (VWF) with its primary platelet receptor, the glycoprotein (GP) Ib-IX-V complex. As an insoluble component of the extracellular matrix (ECM) of endothelial cells, VWF can directly initiate platelet adhesion. Circulating plasma VWF en-hances matrix VWF activity by binding to structures that become exposed to flowing blood, notably collagen type I and III in deeper layers of the vessel along with microfibrillar collagen type VI in the subendothelium. Moreover, plasma VWF is required to support platelet-to-platelet adhesion - i. e. aggregation - which promotes thrombus growth and consolidation. For these reasons, understanding how plasma VWF interaction with platelet receptors is regulated, particularly any distinctive features of GPIb binding to soluble as opposed to immobilized VWF, is of paramount importance in vascular biology. This brief review will highlight knowledge acquired and key problems that remain to be solved to elucidate fully the role of VWF in normal haemostasis and pathological thrombosis.
Collapse
Affiliation(s)
- Z M Ruggeri
- Zaverio M. Ruggeri, MD, The Scripps Research Institute, Maildrop: MEM 175, 10550 North Torrey Pines Road, La Jolla, California 92037, USA, Tel. 858/784 89 50, Fax 858/784 20 26, E-mail:
| | | |
Collapse
|
34
|
|
35
|
Gay LJ, Day J, LeBoeuf S, Ritland M, Ruggeri ZM, Ruf W, Felding BH. Abstract B19: Brain metastasis depends on tumor cell initiated coagulation. Cancer Res 2015. [DOI: 10.1158/1538-7445.chtme14-b19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The incidence of brain metastasis exceeds that of primary brain tumors tenfold and is most frequently associated with lung cancer, breast cancer and melanoma. Despite a prognosis of only 6-9 months for patients with brain metastases, mechanisms of tumor cell brain colonization from the blood stream are unknown. Understanding this step could enable effective therapeutic strategies to prevent the development of incurable metastatic brain disease.
We found that blood borne metastatic cancer cells reside within the cerebral microvasculature for several days and associate with platelets while crossing the blood brain barrier. Intravascular tumor cell survival and extravasation during this time may critically limit the success of brain metastasis. Activation of coagulation, platelets and fibrin formation contribute to tumor progression, cancer-associated thrombosis and metastatic spread to peripheral organs. However the function of coagulation in the seeding of brain metastases is unknown.
Aims: We evaluated whether tumor cell-expressed tissue factor, a key activator of coagulation, promotes tumor cell seeding of brain metastases by initiating critical tumor cell-vascular interactions.
Methods: We developed models of experimental brain metastasis to study how intravascular tumor cells cooperate with the coagulation system during early stages of brain colonization to survive and cross the blood brain barrier. Human breast cancer cells, injected into the left cardiac ventricle of immune deficient mice, are tracked during the initial phase of brain metastasis and progressive metastatic brain disease by detailed and quantitative histological analyses. We address how coagulation contributes to brain metastasis by targeting human tissue factor with specific inhibitory antibodies. We use ex-vivo bioluminescence imaging and immunohistochemical analyses at later stages of brain metastasis to determine the extent to which an early, transient treatment will result in long-term inhibition of brain metastatic disease.
Results: We demonstrate that inhibition of tissue factor expressed by tumor cells reduces brain colonization. Targeting of tissue factor inhibits development of breast cancer brain metastasis and extends animal survival. We find that tissue factor properties which initiate coagulation or promote cytoprotective signaling pathways differentially contribute to brain metastasis development. Our findings indicate that the inhibition of coagulation can prevent the seeding of breast cancer cells into the brain.
Conclusions: Our studies provide mechanistic insights into the process of tumor cell brain colonization and identify targets for development of therapeutics to prevent cancer metastasis to the brain and enhance patient survival.
Citation Format: Laurie J. Gay, John Day, Sarah LeBoeuf, Melissa Ritland, Zaverio M. Ruggeri, Wolfram Ruf, Brunhilde H. Felding. Brain metastasis depends on tumor cell initiated coagulation. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr B19. doi:10.1158/1538-7445.CHTME14-B19
Collapse
Affiliation(s)
| | - John Day
- The Scripps Research Institute, La Jolla, CA
| | | | | | | | - Wolfram Ruf
- The Scripps Research Institute, La Jolla, CA
| | | |
Collapse
|
36
|
Mendolicchio GL, Zavalloni D, Bacci M, Roveda M, Quagliuolo V, Anselmi CV, Rota LL, Ruggeri ZM. Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance. Thromb Haemost 2014; 113:664-7. [PMID: 25428265 DOI: 10.1160/th14-09-0751] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 09/25/2014] [Indexed: 11/05/2022]
Affiliation(s)
- Grazia Loredana Mendolicchio
- Grazia Loredana Mendolicchio, MD, PhD, Laboratori di Ricerca Emostasi e Trombosi, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milano), Italy, Tel.: +39 02 8224 4630, Fax: +39 02 8224 4691, E-mail:
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Koltsova EK, Sundd P, Zarpellon A, Ouyang H, Mikulski Z, Zampolli A, Ruggeri ZM, Ley K. Genetic deletion of platelet glycoprotein Ib alpha but not its extracellular domain protects from atherosclerosis. Thromb Haemost 2014; 112:1252-63. [PMID: 25104056 DOI: 10.1160/th14-02-0130] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Accepted: 06/02/2014] [Indexed: 12/20/2022]
Abstract
The pathogenesis of atherosclerosis involves the interplay of haematopoietic, stromal and endothelial cells. Platelet interactions with endothelium and leukocytes are pivotal for atherosclerosis promotion. Glycoprotein (GP) Ibα is the ligand-binding subunit of the platelet GPIb-IX-V receptor complex; its deficiency causes the Bernard-Soulier syndrome (BSS), characterised by absent platelet GPIb-IX-V, macrothrombocytopenia and bleeding. We designed this study to determine the role of platelet GPIbα in the pathogenesis of atherosclerosis using two unique knockout models. Ldlr-/- mice were reconstituted with wild-type (wt), GPIbα-/- (lacks GPIbα) or chimeric IL-4R/GPIbα-Tg (lacks GPIbα extracellular domain) bone marrow and assayed for atherosclerosis development after feeding with pro-atherogenic "western diet". Here, we report that Ldlr-/-mice reconstituted with GPIbα-/- bone marrow developed less atherosclerosis compared to wt controls; accompanied by augmented accumulation of pro-inflammatory CD11b+ and CD11c+ myeloid cells, reduced oxLDL uptake and decreased TNF and IL 12p35 gene expression in the aortas. Flow cytometry and live cell imaging in whole blood-perfused microfluidic chambers revealed reduced platelet-monocyte aggregates in GPIbα-/- mice, which resulted in decreased monocyte activation. Interestingly, Ldlr-/-mice reconstituted with IL-4R/GPIbα-Tg bone marrow, producing less abnormal platelets, showed atherosclerotic lesions similar to wt mice. Platelet interaction with blood monocytes and accumulation of myeloid cells in the aortas were also essentially unaltered. Moreover, only complete GPIbα ablation altered platelet microparticles and CCL5 chemokine production. Thus, atherosclerosis reduction in mice lacking GPIbα may not result from the defective GPIbα-ligand binding, but more likely is a consequence of functional defects of GPIbα-/- platelets and reduced blood platelet counts.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - K Ley
- Klaus Ley, MD, Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA, Fax: +1 858 752 6985, E-mail:
| |
Collapse
|
38
|
Foglieni C, Marchese P, Lombardi M, Mantione ME, Baccellieri D, Ferrara D, Castellano R, Kamami K, Ruf W, Ruggeri ZM. P231Molecular and cellular components of human carotid artery plaque related to thrombogenicity. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu082.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Koltsova E, Sundd P, Zarpellon A, Ruggeri ZM, Ley K. Abstract 58: Delayed Atherosclerosis in a Mouse Model of Bernard-Soulier Syndrome is Independent of Glycoprotein Ibα Extracytoplasmic Domain Deficiency. Arterioscler Thromb Vasc Biol 2014. [DOI: 10.1161/atvb.34.suppl_1.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The pathogenesis of atherosclerosis involves the interplay of blood, stromal and endothelial cells; platelet interactions with vascular endothelium and leukocytes promote atherosclerosis. Glycoprotein (GP) Iba is the ligand-binding subunit of the platelet GPIb-IX-V adhesion receptor complex; its deficiency causes the Bernard-Soulier syndrome (BSS), characterized by absent platelet GPIb-IX-V, macrothrombocytopenia and bleeding. We found that
Ldlr-/-
mice reconstituted with
GPIb
a
-/-
as compared to wild type control developed delayed atherosclerosis associated with reduced platelet binding to blood myeloid cells and reduced accumulation of CD11b
+
and CD11c
+
myeloid cells in the aortas. Live imaging in whole blood-perfused microfluidic chambers revealed reduced platelet-monocyte aggregates in
GPIb
a
-/-
mice, which also showed decreased TNF in blood monocytes along with decreased TNF and IL12p35, but enhanced arginase1 in aortas. In contrast,
Ldlr-/-
mice reconstituted with chimeric IL-4R/
GPIb
a-Tg bone marrow produce platelets expressing GPIb-IX-V without the GPIba extracytoplasmic domain but less abnormal with respect to size and count and showed atherosclerotic lesion sizes similar to control mice. In conclusion, reduced platelet interactions with myeloid cells and delayed onset of atherosclerosis are not caused by defective GPIba-ligand binding but may result from the low platelet count and, possibly, other functional defects of BSS platelets.
Collapse
Affiliation(s)
- Ekaterina Koltsova
- Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA
| | - Prithu Sundd
- Bioengineering, Vascular Medicine Institute, Univ of Pittsburgh Sch of Medicine, Pittsburgh, PA
| | | | - Zaverio M Ruggeri
- Molecular and Experimental Medicine, Scripps Rsch Institute, La Jolla, CA
| | - Klaus Ley
- Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA
| |
Collapse
|
40
|
Yokota N, Zarpellon A, Chakrabarty S, Bogdanov VY, Gruber A, Castellino FJ, Mackman N, Ellies LG, Weiler H, Ruggeri ZM, Ruf W. Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost 2014; 12:71-81. [PMID: 24175924 PMCID: PMC3947224 DOI: 10.1111/jth.12442] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Indexed: 12/12/2022]
Abstract
BACKGROUND Tumor cell tissue factor (TF)-initiated coagulation supports hematogenous metastasis by fibrin formation, platelet activation and monocyte/macrophage recruitment. Recent studies identified host anticoagulant mechanisms as a major impediment to successful hematogenous tumor cell metastasis. OBJECTIVE Here we address mechanisms that contribute to enhanced metastasis in hyperthrombotic mice with functional thrombomodulin deficiency (TM(Pro) mice). METHODS Pharmacological and genetic approaches were combined to characterize relevant thrombin targets in a mouse model of experimental hematogenous metastasis. RESULTS TF-dependent, but contact pathway-independent, syngeneic breast cancer metastasis was associated with marked platelet hyperreactivity and formation of leukocyte-platelet aggregates in immune-competent TM(Pro) mice. Blockade of CD11b or genetic deletion of platelet glycoprotein Ibα excluded contributions of these receptors to enhanced platelet-dependent metastasis in hyperthrombotic mice. Mice with very low levels of the endothelial protein C receptor (EPCR) did not phenocopy the enhanced metastasis seen in TM(Pro) mice. Genetic deletion of the thrombin receptor PAR1 or endothelial thrombin signaling targets alone did not diminish enhanced metastasis in TM(Pro) mice. Combined deficiency of PAR1 on tumor cells and the host reduced metastasis in TM(Pro) mice. CONCLUSIONS Metastasis in the hyperthrombotic TM(Pro) mouse model is mediated by platelet hyperreactivity and contributions of PAR1 signaling on tumor and host cells.
Collapse
Affiliation(s)
- Naho Yokota
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA
| | - Alessandro Zarpellon
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
| | - Sagarika Chakrabarty
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA
| | - Vladimir Y. Bogdanov
- Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH
| | - András Gruber
- Departments of Biomedical Engineering and Medicine, Oregon Health and Science University, Portland, OR
| | | | - Nigel Mackman
- Department of Medicine, University of North Carolina, Chapel Hill, NC
| | - Lesley G. Ellies
- Department of Pathology, University of California San Diego, La Jolla, CA
| | - Hartmut Weiler
- Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI
| | - Zaverio M. Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
| | - Wolfram Ruf
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA
| |
Collapse
|
41
|
Khanicheh E, Qi Y, Xie A, Mitterhuber M, Xu L, Mochizuki M, Daali Y, Jaquet V, Krause KH, Ruggeri ZM, Kuster GM, Lindner JR, Kaufmann BA. Molecular imaging reveals rapid reduction of endothelial activation in early atherosclerosis with apocynin independent of antioxidative properties. Arterioscler Thromb Vasc Biol 2013; 33:2187-92. [PMID: 23908248 DOI: 10.1161/atvbaha.113.301710] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Antioxidative drugs continue to be developed for the treatment of atherosclerosis. Apocynin is an nicotinamide adenine dinucleotide phosphate oxidase inhibitor with anti-inflammatory properties. We used contrast-enhanced ultrasound molecular imaging to assess whether short-term apocynin therapy in atherosclerosis reduces vascular oxidative stress and endothelial activation APPROACH AND RESULTS Genetically modified mice with early atherosclerosis were studied at baseline and after 7 days of therapy with apocynin (4 mg/kg per day IP) or saline. Contrast-enhanced ultrasound molecular imaging of the aorta was performed with microbubbles targeted to vascular cell adhesion molecule 1 (VCAM-1; MB(V)), to platelet glycoprotein Ibα (MB(Pl)), and control microbubbles (MB(Ctr)). Aortic vascular cell adhesion molecule 1 was measured using Western blot. Aortic reactive oxygen species generation was measured using a lucigenin assay. Hydroethidine oxidation was used to assess aortic superoxide generation. Baseline signal for MBV (1.3 ± 0.3 AU) and MB(Pl )(1.5 ± 0.5 AU) was higher than for MBCtr (0.5 ± 0.2 AU; P<0.01). In saline-treated animals, signal did not significantly change for any microbubble agent, whereas short-term apocynin significantly (P<0.05) reduced vascular cell adhesion molecule 1 and platelet signal (MBV: 0.3 ± 0.1; MBPl: 0.4 ± 0.1; MBCtr: 0.3 ± 0.2 AU; P=0.6 between agents). Apocynin reduced aortic vascular cell adhesion molecule 1 expression by 50% (P<0.05). However, apocynin therapy did not reduce reactive oxygen species content, superoxide generation, or macrophage content. CONCLUSIONS Short-term treatment with apocynin in atherosclerosis reduces endothelial cell adhesion molecule expression. This change in endothelial phenotype can be detected by molecular imaging before any measurable decrease in macrophage content and is not associated with a detectable change in oxidative burden.
Collapse
Affiliation(s)
- Elham Khanicheh
- Division of Cardiology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Rothmeier AS, Furlan-Freguia C, Marchese P, Petrich B, Ruggeri ZM, Ginsberg MH, Ruf W. Abstract 70: P2X7-Induced Thiol-Disulfide Exchange is Critical for the Coupling of Coagulation and Inflammation. Arterioscler Thromb Vasc Biol 2013. [DOI: 10.1161/atvb.33.suppl_1.a70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Macrophages are important players in the maintenance of tissue homeostasis, but promote inflammation through the release of IL1β triggered by danger signals in form of extracellular ATP that activates the purinergic P2X7 receptor. We found that P2X7 signaling also contributes to thrombosis by inducing thiol-dependent tissue factor (TF) activation coupled to procoagulant microparticles (MP) release. In the present study, we identified thiol-regulated proteins released on MP and based on this information delineated key steps in the P2X7-induced generation of prothrombotic TF
+
MP. We find that TF procoagulant activity of LPS/IFNγ primed macrophages is controlled by internalization through the arf6/integrin-recycling pathway. Activation of P2X7 inactivates arf6 and prevents TF internalization, but additional steps are required to generate highly procoagulant MP carrying TF and integrin β1. Imaging of cell surface TF by confocal microscopy shows translocation of TF onto filopodia that form in response to P2X7 activation. Blocking raft mobility does not inhibit filopodia formation, but rather specifically prevents TF and integrin β1 trafficking and release on MP. We show that filopodia formation is dependent on thioredoxin reductase (TRXR). Remarkably, thioredoxin (TRX), the direct substrate of TRXR, is entirely released from the cytosol. Pharmacological inhibition of TRXR blocks both TRX release and reductive changes on the cell surface and MP, identifying the molecular events that change the extracellular redox environment. TRXR-mediated externalization of TRX was also required for activation of the inflammasome and caspase1 leading to IL1β processing and release. These data elucidate the molecular events required for the generation of highly procoagulant TF
+
MP and identifies TRXR-TRX dependent thiol-disulfide exchange as common upstream regulator responsible for the induction of inflammation and coagulation in innate immune cells.
Collapse
Affiliation(s)
- Andrea S Rothmeier
- Immunology and Microbial Science, The Scripps Rsch Institute, La Jolla, CA
| | | | - Patrizia Marchese
- Molecular and Experimental Medicine, The Scripps Rsch Institute, La Jolla, CA
| | - Brian Petrich
- Dept of Medicine, Univ of California San Diego, La Jolla, CA
| | - Zaverio M Ruggeri
- Molecular and Experimental Medicine, The Scripps Rsch Institute, La Jolla, CA
| | - Mark H Ginsberg
- Dept of Medicine, Univ of California San Diego, La Jolla, CA
| | - Wolfram Ruf
- Immunology and Microbial Science, The Scripps Rsch Institute, La Jolla, CA
| |
Collapse
|
43
|
Habart D, Cheli Y, Nugent DJ, Ruggeri ZM, Kunicki TJ. Conditional knockout of integrin α2β1 in murine megakaryocytes leads to reduced mean platelet volume. PLoS One 2013; 8:e55094. [PMID: 23359821 PMCID: PMC3554675 DOI: 10.1371/journal.pone.0055094] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Accepted: 12/22/2012] [Indexed: 01/16/2023] Open
Abstract
We have engineered a transgenic mouse on a C57BL/6 background that bears a floxed Itga2 gene. The crossing of this mouse strain to transgenic mice expressing Cre recombinase driven by the megakaryocyte (MK)-specific Pf4 promoter permits the conditional knockout of Itga2 in the MK/platelet lineage. Mice lacking MK α2β1 develop normally, are fertile, and like their systemic α2β1 knockout counterparts, exhibit defective adhesion to and aggregation induced by soluble type I collagen and a delayed onset to low dose fibrillar collagen-induced aggregation, results consistent with blockade or loss of platelet α2β1. At the same time, we observed a significant reduction in mean platelet volume, which is consistent with the reported role of α2β1 in MK maturation and proplatelet formation in vivo. This transgenic mouse strain bearing a floxed Itga2 gene will prove valuable to distinguish in vivo the temporal and spatial contributions of α2 integrin in selected cell types.
Collapse
Affiliation(s)
- David Habart
- Roon Research Center for Arteriosclerosis and Thrombosis, The Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States of America
| | - Yann Cheli
- Roon Research Center for Arteriosclerosis and Thrombosis, The Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States of America
| | - Diane J. Nugent
- Hematology Research, CHOC Children's Hospital, Orange, California, United States of America
| | - Zaverio M. Ruggeri
- Roon Research Center for Arteriosclerosis and Thrombosis, The Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States of America
| | - Thomas J. Kunicki
- Roon Research Center for Arteriosclerosis and Thrombosis, The Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States of America
- Hematology Research, CHOC Children's Hospital, Orange, California, United States of America
- * E-mail:
| |
Collapse
|
44
|
|
45
|
Andrews RK, Aster RH, Atkinson BT, Barnard MR, Bavry AA, Bayer AS, Beaulieu LM, Berndt MC, Berny-Lang MA, Bhatt DL, Bizzaro N, Bledzka K, Bouchard BA, Brass LF, Bray PF, Briggs C, Bussel JB, Cattaneo M, Chakravorty S, Chong BH, Clemetson J, Clemetson KJ, Coller BS, Covic L, Davì G, del Zoppo GJ, Dowling MR, Dubois C, Eisert WG, Evangelista V, Flaumenhaft R, Freedman JE, Freedman J, Frelinger AL, Furie BC, Furie B, Gardiner C, Gawaz M, Geisler T, Greinacher A, Gurbel PA, Harrison P, Hartwig JH, Hayward CP, Hughes CE, Ikeda Y, Israels SJ, Italiano JE, Jackson S, Jain S, Jones CI, Josefsson EC, Kaplan C, Kile BT, Kimura Y, Klement GL, Kolandaivelu K, Kuliopulos A, Kuter DJ, Lambert MP, Langer HF, Lebois M, Levin J, Lordkipanidzé M, Ma YQ, Mannucci PM, McCrae KR, Merrill-Skoloff G, Michelson AD, Moffat KA, Mutch NJ, Newman DK, Newman PE, Ni H, Nieuwland R, Ouwehand WH, Parsons J, Patrono C, Perrotta PL, Pesho MM, Plow EF, Politt AY, Poncz M, Poon MC, Provost P, Psaila B, Rao AK, Rinder HM, Roberts IA, Rondina MT, Ruggeri ZM, Santilli F, Schwertz H, Shai E, Silveira JR, Smith BR, Smith MC, Smyth SS, Snyder EL, Sobel M, Soranzo N, Stalker TJ, Sturk A, Sudo T, Sullivan S, Tantry US, Tefferi A, Tracy PB, Tsai HM, van der Pol E, Varon D, Vazzana N, Vieira-de-Abreu A, Wannemacher K, Ware J, Warkentin TE, Watson SP, Weyrich AS, White JG, Wilcox DA, Yeaman MR, Zhang P, Zhu L, Zimmerman GA. List of Contributors. Platelets 2013. [DOI: 10.1016/b978-0-12-387837-3.00072-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJT, Tormoen GW, Zhao Y, Ruggeri ZM, Kaufmann BA, Lindner JR. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging 2012; 6:74-82. [PMID: 23239832 DOI: 10.1161/circimaging.112.975193] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND In atherosclerosis, local generation of reactive oxygen species amplifies the inflammatory response and contributes to plaque vulnerability. We used molecular imaging to test whether inhibition of NADPH oxidase with apocynin would reduce endothelial inflammatory activation and endothelial-platelet interactions, thereby interrupting progression to high-risk plaque phenotype. METHODS AND RESULTS Mice deficient for both the low-density lipoprotein receptor and Apobec-1 were studied at 30 weeks of age and again after 10 weeks with or without apocynin treatment (10 or 50 mg/kg per day orally). In vivo molecular imaging of vascular cell adhesion molecule-1 (VCAM 1) P-selectin, and platelet glycoprotein-1bα (GPIbα) in the thoracic aorta was performed with targeted contrast-enhanced ultrasound molecular imaging. Arterial elastic modulus and pulse wave transit time were assessed using ultrahigh frequency ultrasound and invasive hemodynamic measurements. Plaque size and composition were assessed by histology. Molecular imaging in nontreated mice detected a 2-fold increase in P-selectin expression, VCAM-1 expression, and platelet adhesion between 30 and 40 weeks of age. Apocynin reduced all of these endothelial events in a dose-dependent fashion (25% and 50% reduction in signal at 40 weeks for low- and high-dose apocynin). Apocynin also decreased aortic elastic modulus and increased the pulse transit time. On histology, apocynin reduced total monocyte accumulation in a dose-dependent manner as well as platelet adhesion, although total plaque area was reduced in only the high-dose apocynin treatment group. CONCLUSIONS Inhibition of NADPH oxidase in advanced atherosclerosis reduces endothelial activation and platelet adhesion, which are likely responsible for the arrest of plaque growth and improvement of vascular mechanical properties.
Collapse
Affiliation(s)
- Yani Liu
- Division of Cardiovascular Medicine, Oregon Health & Science University, Portland, OR 97239, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Du VX, Os G, Kremer Hovinga JA, Dienava-Verdoold I, Wollersheim J, Ruggeri ZM, Fijnheer R, Groot PG, Laat B. Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura. Br J Haematol 2012; 159:94-103. [DOI: 10.1111/bjh.12004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Accepted: 06/25/2012] [Indexed: 11/28/2022]
Affiliation(s)
| | | | - Johanna A. Kremer Hovinga
- University Clinic of Haematology and Central Haematology Laboratory; Bern University Hospital and the University of Bern; Bern; Switzerland
| | | | - Jacques Wollersheim
- Sanquin Research; Sanquin Blood Supply Foundation; Amsterdam; The Netherlands
| | - Zaverio M. Ruggeri
- Roon Research Center for Arteriosclerosis and Thrombosis; Department of Molecular and Experimental Medicine; The Scripps Research Institute; La Jolla; CA; USA
| | - Rob Fijnheer
- Clinical Chemistry and Haematology; University Medical Centre; Utrecht; The Netherlands
| | - Philip G. Groot
- Clinical Chemistry and Haematology; University Medical Centre; Utrecht; The Netherlands
| | | |
Collapse
|
48
|
Doshi N, Orje JN, Molins B, Smith JW, Mitragorti S, Ruggeri ZM. Platelet mimetic particles for targeting thrombi in flowing blood. Adv Mater 2012; 24:3864-9. [PMID: 22641451 PMCID: PMC3483800 DOI: 10.1002/adma.201200607] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Revised: 03/27/2012] [Indexed: 05/03/2023]
Affiliation(s)
- Nishit Doshi
- Department of Chemical Engineering, University of California, Santa Barbara, CA
| | - Jennifer N. Orje
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
| | - Blanca Molins
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
| | | | - Samir Mitragorti
- Department of Chemical Engineering, University of California, Santa Barbara, CA
| | - Zaverio M. Ruggeri
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
| |
Collapse
|
49
|
Li C, Piran S, Chen P, Lang S, Zarpellon A, Jin JW, Zhu G, Reheman A, van der Wal DE, Simpson EK, Ni R, Gross PL, Ware J, Ruggeri ZM, Freedman J, Ni H. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011; 121:4537-47. [PMID: 22019589 PMCID: PMC3204841 DOI: 10.1172/jci57850] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2011] [Accepted: 08/26/2011] [Indexed: 11/17/2022] Open
Abstract
Fetal and neonatal immune thrombocytopenia (FNIT) is a severe bleeding disorder caused by maternal antibody-mediated destruction of fetal/neonatal platelets. It is the most common cause of severe thrombocytopenia in neonates, but the frequency of FNIT-related miscarriage is unknown, and the mechanism(s) underlying fetal mortality have not been explored. Furthermore, although platelet αIIbβ3 integrin and GPIbα are the major antibody targets in immune thrombocytopenia, the reported incidence of anti-GPIbα-mediated FNIT is rare. Here, we developed mouse models of FNIT mediated by antibodies specific for GPIbα and β3 integrin and compared their pathogenesis. We found, unexpectedly, that miscarriage occurred in the majority of pregnancies in our model of anti-GPIbα-mediated FNIT, which was far more frequent than in anti-β3-mediated FNIT. Dams with anti-GPIbα antibodies exhibited extensive fibrin deposition and apoptosis/necrosis in their placentas, which severely impaired placental function. Furthermore, anti-GPIbα (but not anti-β3) antiserum activated platelets and enhanced fibrin formation in vitro and thrombus formation in vivo. Importantly, treatment with either intravenous IgG or a monoclonal antibody specific for the neonatal Fc receptor efficiently prevented anti-GPIbα-mediated FNIT. Thus, the maternal immune response to fetal GPIbα causes what we believe to be a previously unidentified, nonclassical FNIT (i.e., spontaneous miscarriage but not neonatal bleeding) in mice. These results suggest that a similar pathology may have masked the severity and frequency of human anti-GPIbα-mediated FNIT, but also point to possible therapeutic interventions.
Collapse
MESH Headings
- Abortion, Spontaneous/etiology
- Abortion, Spontaneous/immunology
- Abortion, Spontaneous/prevention & control
- Animals
- Blood Platelets/immunology
- Disease Models, Animal
- Female
- Histocompatibility Antigens Class I/immunology
- Histocompatibility, Maternal-Fetal/immunology
- Humans
- Immunoglobulins, Intravenous/therapeutic use
- Integrin beta3/genetics
- Integrin beta3/immunology
- Mice
- Mice, Inbred BALB C
- Mice, Knockout
- Platelet Glycoprotein GPIb-IX Complex/genetics
- Platelet Glycoprotein GPIb-IX Complex/immunology
- Pregnancy
- Receptors, Fc/antagonists & inhibitors
- Receptors, Fc/immunology
- Thrombocytopenia, Neonatal Alloimmune/etiology
- Thrombocytopenia, Neonatal Alloimmune/immunology
Collapse
Affiliation(s)
- Conglei Li
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Siavash Piran
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Pingguo Chen
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Sean Lang
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Alessandro Zarpellon
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Joseph W. Jin
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Guangheng Zhu
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Adili Reheman
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Dianne E. van der Wal
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Elisa K. Simpson
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Ran Ni
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Peter L. Gross
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Jerry Ware
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Zaverio M. Ruggeri
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - John Freedman
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| | - Heyu Ni
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Toronto Platelet Immunobiology Group and Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada.
Canadian Blood Services, Toronto, Ontario, Canada.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Medicine and
Department of Physiology, University of Toronto, Ontario, Canada
| |
Collapse
|
50
|
Furlan-Freguia C, Marchese P, Gruber A, Ruggeri ZM, Ruf W. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest 2011; 121:2932-44. [PMID: 21670495 DOI: 10.1172/jci46129] [Citation(s) in RCA: 128] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2011] [Accepted: 04/27/2011] [Indexed: 12/23/2022] Open
Abstract
Thrombosis is initiated by tissue factor (TF), a coagulation cofactor/receptor expressed in the vessel wall, on myeloid cells, and on microparticles (MPs) with variable procoagulant activity. However, the molecular pathways that generate prothrombotic TF in vivo are poorly defined. The oxidoreductase protein disulfide isomerase (PDI) is thought to be involved in the activation of TF. Here, we found that in mouse myeloid cells, ATP-triggered signaling through purinergic receptor P2X, ligand-gated ion channel, 7 (P2X7 receptor; encoded by P2rx7) induced activation (decryption) of TF procoagulant activity and promoted release of TF+ MPs from macrophages and SMCs. The generation of prothrombotic MPs required P2X7 receptor-dependent production of ROS leading to increased availability of solvent-accessible extracellular thiols. An antibody to PDI with antithrombotic activity in vivo attenuated the release of procoagulant MPs. In addition, P2rx7-/- mice were protected from TF-dependent FeCl3-induced carotid artery thrombosis. BM chimeras revealed that P2X7 receptor prothrombotic function was present in both hematopoietic and vessel wall compartments. In contrast, an alternative anti-PDI antibody showed activities consistent with cellular activation typically induced by P2X7 receptor signaling. This anti-PDI antibody restored TF-dependent thrombosis in P2rx7-/- mice. These data suggest that PDI regulates a critical P2X7 receptor-dependent signaling pathway that generates prothrombotic TF, defining a link between inflammation and thrombosis with potential implications for antithrombotic therapy.
Collapse
Affiliation(s)
- Christian Furlan-Freguia
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, USA
| | | | | | | | | |
Collapse
|